Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...

During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and ...

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus host ...

Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for ...

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. Authors: ... Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia. Previous.

Patients who underwent stem cell transplants (SCTs) involving mismatched unrelated donors (MMUDs) had a 1-year overall ...

Graft versus Host Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted GvHD epidemiology in the 7MM, i.e., the United States ...

Pharmacologic suppression of graft-versus-host disease (GVHD) is critical to the success of hematopoietic stem cell transplantation (HSCT). 1 The use of cyclophosphamide for GVHD prevention has ...

So, we marked another World Sickle Cell Day on Thursday, June 19. But truthfully, what was there to celebrate? I can’t speak ...

MiNK Therapeutics receives an NIAID grant to develop iNKT cell therapies for preventing graft-versus-host disease in stem cell transplants. MiNK Therapeutics, Inc., a biopharmaceutical company ...

NeuroScientific Biopharmaceuticals has acquired unlisted Perth-based Isopogen for $5.1 million, gaining control of the ...